ASX ANNOUNCEMENT

NON-MELANOMA SKIN CANCER TRIAL ADVANCES TO BASAL CELL CARCINOMA (BCC) COHORT FOLLOWING 2ND SET OF ENCOURAGING SAFETY & EFFICACY SIGNALS

Highlights:

- **Expansion into Basal Cell Carcinoma (BCC) patients:** The Safety Review Committee (SRC) has approved expanding the patient population in the Non-Melanoma Skin Cancer (NMSC) trial to BCC patients
- **Further Encouraging Results:** BCC decision follows another set of results from a new cohort of six squamous cell carcinoma (SCC) patient readouts that include:
    - Continued strong safety data including no adverse effects nor observed pain
    - Reductions in size of lesions relative to baseline ($p<0.05$)
    - Complete resolution observed in select cases, with durability under evaluation
    - Consistent fluorescence signals that further validate theragnostic potential
- **Larger Addressable Market:** BCCs account for 80% of all skin cancers[1] and this new cohort is in the final part of the current NMSC trial. Expansion to this group of patients was not possible until satisfactory safety results were obtained in the SCC patients.

MELBOURNE (AUSTRALIA) 21 April 2026: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**") announces the next phase in development of INV043 for non-melanoma skin cancer (**NMSC**), progressing its clinical trial to the final Part 3 and expanding to patients with Basal Cell Carcinoma (**BCC**) – the largest and most prevalent form representing approximately 80% of all of skin cancers[1].

The approval from the SRC to expand to this patient population follows the second set of preliminary unaudited data demonstrating a consistently favourable safety profile and encouraging early efficacy signals in a new cohort of six squamous cell carcinoma (**SCC**) patient readouts. Invion released the early results from the first six SCC patients last year[2].

BCCs are difficult to grow in animal models and so being able to expand the NMSC trial to BCCs opens significant additional pathways to market. Expansion to this group of patients was not possible until satisfactory safety results were obtained in the SCC patients.

Invion's Executive Chair and CEO, Prof Thian Chew, commented:

> *"We see the expansion into BCC as a value-enhancing milestone for INV043. With the additional data confirming a strong safety profile and encouraging early efficacy signals in SCC patients, we are now positioned to generate the human BCC data that will bolster our Phase II strategy.*
>
> *"Further, the positive observations in the NMSC trial will further support our upcoming anogenital trial, which will use the same topical formulation of INV043."*

[1] https://www.yalemedicine.org/conditions/basal-cell-carcinoma#
[2] https://investors.inviongroup.com/announcements/6978964

Clinical Observations from New SCC Cohort

Consistent with earlier findings from the Safety Review Committee (**SRC**)[2], no dose-limiting toxicities (**DLTs**) or treatment-related safety concerns have been identified to date. The treatment continues to be well tolerated, with clinician feedback indicating no pain during or after treatment, comparing favourably to currently approved photodynamic therapy (PDT) treatments.

Importantly, there continues to be encouraging efficacy signals in this latest patient cohort with early data showing:

- Continued strong safety data including no adverse effects nor observed pain
- Reductions in size of lesions relative to baseline ($p<0.05$)
- Complete resolution observed in select cases, with durability under evaluation; and
- Consistent fluorescence signals that further validate theragnostic potential with red light (660nm) activating the therapeutic effect and violet light (405nm) enabling fluorescence-based visualisation of lesions.





Next Steps

Invion will now initiate recruitment for the BCC cohort, building on the results observed in SCC patients. The Company will continue treating and monitoring participants in the current cohort to further monitor safety and characterise lesion-level responses. Invion will provide further updates where appropriate, as the trial progresses.

This announcement was approved for release by Invion's Board of Directors.

***Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions**: https://investors.inviongroup.com/*

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing Photosoft™ technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".